

# Elias J Jabbour

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9319541/publications.pdf>

Version: 2024-02-01

341  
papers

22,445  
citations

6613

79  
h-index

12946

131  
g-index

345  
all docs

345  
docs citations

345  
times ranked

15235  
citing authors

#	ARTICLE	IF	CITATIONS
1	Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Cancer</i> , 2006, 106, 1090-1098.	4.1	550
2	Inotuzumab ozogamicin, an anti-CD22 $\alpha$ –calicheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. <i>Lancet Oncology</i> , The, 2012, 13, 403-411.	10.7	401
3	Ibrutinib and Venetoclax for First-Line Treatment of CLL. <i>New England Journal of Medicine</i> , 2019, 380, 2095-2103.	27.0	388
4	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. <i>Cancer Discovery</i> , 2019, 9, 370-383.	9.4	380
5	Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). <i>Blood</i> , 2014, 123, 494-500.	1.4	364
6	Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. <i>Blood</i> , 2010, 116, 4422-4429.	1.4	336
7	Clinical experience with the BCL2 inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. <i>American Journal of Hematology</i> , 2018, 93, 401-407.	4.1	336
8	Acute myeloid leukemia: current progress and future directions. <i>Blood Cancer Journal</i> , 2021, 11, 41.	6.2	313
9	Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. <i>Blood</i> , 2012, 119, 1981-1987.	1.4	298
10	BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. <i>Cancer Cell</i> , 2014, 26, 428-442.	16.8	292
11	Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. <i>American Journal of Hematology</i> , 2018, 93, 442-459.	4.1	291
12	Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. <i>Blood</i> , 2017, 129, 572-581.	1.4	285
13	Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. <i>Blood</i> , 2007, 110, 4005-4011.	1.4	284
14	Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. <i>Cancer</i> , 2013, 119, 2728-2736.	4.1	265
15	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. <i>Journal of Hematology and Oncology</i> , 2019, 12, 1.	17.0	257
16	Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. <i>Blood</i> , 2016, 127, 1863-1869.	1.4	253
17	Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 1099-1110.	10.7	249
18	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 1547-1555.	10.7	245

#	ARTICLE	IF	CITATIONS
19	Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. <i>Cancer</i> , 2010, 116, 3830-3834.	4.1	241
20	Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase. <i>Journal of Clinical Oncology</i> , 2010, 28, 392-397.	1.6	231
21	The distribution of Tâ€cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 1470-1481.	4.1	229
22	Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. <i>American Journal of Hematology</i> , 2020, 95, 691-709.	4.1	229
23	Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 398-404.	1.6	227
24	Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. <i>Lancet Haematology</i> ,the, 2015, 2, e186-e193.	4.6	227
25	Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. <i>Blood</i> , 2017, 129, 1275-1283.	1.4	214
26	Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and longâ€term survival followâ€up from the randomized, phase 3 INOâ€VATE study. <i>Cancer</i> , 2019, 125, 2474-2487.	4.1	210
27	Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. <i>Lancet, The</i> , 2020, 396, 1885-1894.	13.7	206
28	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. <i>Lancet Haematology</i> ,the, 2020, 7, e724-e736.	4.6	201
29	New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. <i>Cancer</i> , 2015, 121, 2517-2528.	4.1	200
30	<i>TP53</i> mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. <i>Cancer</i> , 2016, 122, 3484-3491.	4.1	200
31	Impact of complete molecular response on survival in patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia. <i>Blood</i> , 2016, 128, 504-507.	1.4	194
32	Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2018, 19, 240-248.	10.7	192
33	Lowâ€dose azacitidine after allogeneic stem cell transplantation for acute leukemia. <i>Cancer</i> , 2009, 115, 1899-1905.	4.1	191
34	Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 653-661.	3.5	191
35	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. <i>Lancet Haematology</i> ,the, 2018, 5, e618-e627.	4.6	190
36	Evolution of decitabine development. <i>Cancer</i> , 2008, 112, 2341-2351.	4.1	187

#	ARTICLE	IF	CITATIONS
37	Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Cancer</i> , 2015, 121, 4158-4164.	4.1	181
38	Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. <i>Blood</i> , 2007, 109, 3214-3218.	1.4	174
39	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 2768-2778.	1.6	173
40	Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. <i>Blood</i> , 2015, 126, 790-797.	1.4	162
41	Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2012, 30, 2204-2210.	1.6	158
42	Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. <i>Lancet Haematology</i> , 2017, 4, e387-e398.	4.6	158
43	HyperCVAD plus ponatinib versus hyperCVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2016, 122, 3650-3656.	4.1	156
44	Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1788-1797.	1.6	156
45	Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. <i>Blood</i> , 2009, 113, 2154-2160.	1.4	151
46	Monoclonal antibodies in acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 4010-4016.	1.4	144
47	Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2016, 17, 496-508.	10.7	142
48	FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. <i>Leukemia</i> , 2020, 34, 682-696.	7.2	140
49	Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. <i>American Journal of Hematology</i> , 2016, 91, 252-265.	4.1	139
50	Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. <i>Cancer</i> , 2007, 109, 2481-2489.	4.1	138
51	Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Cancer Discovery</i> , 2021, 11, 1440-1453.	9.4	137
52	The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Blood</i> , 2011, 118, 4541-4546.	1.4	133
53	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. <i>Lancet Oncology</i> , 2015, 16, 1025-1036.	10.7	129
54	Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 897-901.	0.4	127

#	ARTICLE	IF	CITATIONS
55	Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. <i>Blood</i> , 2013, 121, 4867-4874.	1.4	124
56	Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Miniâ€“Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosomeâ€“Negative Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2018, 4, 230.	7.1	124
57	Results of phase 2 randomized study of lowâ€“dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. <i>Cancer</i> , 2015, 121, 556-561.	4.1	122
58	Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. <i>Blood</i> , 2016, 127, 1269-1275.	1.4	119
59	Current and emerging treatment options in chronic myeloid leukemia. <i>Cancer</i> , 2007, 109, 2171-2181.	4.1	115
60	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. <i>Cancer</i> , 2017, 123, 4391-4402.	4.1	114
61	Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. <i>Cancer</i> , 2007, 109, 265-273.	4.1	113
62	Activity of the oral mitogenâ€“activated protein kinase kinase inhibitor trametinib in <sc><i>RAS</i></sc>â€“mutant relapsed or refractory myeloid malignancies. <i>Cancer</i> , 2016, 122, 1871-1879.	4.1	113
63	Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. <i>Blood Advances</i> , 2020, 4, 1311-1320.	5.2	106
64	Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. <i>Cancer</i> , 2010, 116, 5568-5574.	4.1	104
65	Adult Acute Myeloid Leukemia. <i>Mayo Clinic Proceedings</i> , 2006, 81, 247-260.	3.0	103
66	Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. <i>Blood</i> , 2011, 118, 6030-6036.	1.4	103
67	Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. <i>Lancet Haematology</i> , the, 2019, 6, e480-e488.	4.6	103
68	Final results of a single institution experience with a pediatricâ€“based regimen, the augmented Berlinâ€“Frankfurtâ€“MÃ¼nster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyperâ€“CVAD regimen. <i>American Journal of Hematology</i> , 2016, 91, 819-823.	4.1	102
69	Minimal residual disease assessed by multiâ€“parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2016, 172, 392-400.	2.5	102
70	Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. <i>Journal of Hematology and Oncology</i> , 2020, 13, 70.	17.0	100
71	Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. <i>American Journal of Hematology</i> , 2019, 94, 257-265.	4.1	99
72	Sorafenib Combined with 5â€“azacytidine in Older Patients with Untreated <i>FLT3</i>â€“TD Mutated Acute Myeloid Leukemia. <i>American Journal of Hematology</i> , 2018, 93, 1136-1141.	4.1	95

#	ARTICLE	IF	CITATIONS
73	Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). <i>Cancer</i> , 2014, 120, 3660-3668.	4.1	91
74	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with <i>FLT3</i> -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1507-1516.	3.5	91
75	Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. <i>Blood</i> , 2011, 118, 4690-4693.	1.4	88
76	Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. <i>Cancer</i> , 2013, 119, 2611-2619.	4.1	88
77	Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. <i>Cancer</i> , 2018, 124, 4044-4055.	4.1	88
78	Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. <i>Blood Advances</i> , 2019, 3, 851-861.	5.2	88
79	Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. <i>Cancer</i> , 2020, 126, 67-75.	4.1	87
80	Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. <i>Lancet Haematology</i> , 2015, 2, e376-e383.	4.6	86
81	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. <i>Blood Advances</i> , 2020, 4, 482-495.	5.2	86
82	Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. <i>Oncotarget</i> , 2016, 7, 14172-14187.	1.8	86
83	Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. <i>Blood</i> , 2006, 108, 1421-1423.	1.4	85
84	NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. <i>Blood Advances</i> , 2019, 3, 922-933.	5.2	84
85	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e29-e37.	4.6	84
86	Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. <i>Blood Advances</i> , 2017, 1, 1312-1323.	5.2	83
87	De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. <i>Cancer</i> , 2021, 127, 2049-2061.	4.1	79
88	Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Cancer</i> , 2018, 124, 2758-2765.	4.1	78
89	Therapeutic implications of menin inhibition in acute leukemias. <i>Leukemia</i> , 2021, 35, 2482-2495.	7.2	76
90	Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. <i>Blood</i> , 2008, 112, 4839-4842.	1.4	75

#	ARTICLE	IF	CITATIONS
91	Hyper- $\text{CVAD}$ plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. <i>American Journal of Hematology</i> , 2018, 93, 91-99.	4.1	74
92	Practical advice for determining the role of <i>BCR-ABL</i> mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. <i>Cancer</i> , 2011, 117, 1800-1811.	4.1	72
93	Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. <i>Blood</i> , 2011, 117, 3641-3647.	1.4	71
94	Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?. <i>Journal of Clinical Oncology</i> , 2011, 29, 4260-4265.	1.6	71
95	Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. <i>Lancet Haematology</i> , 2019, 6, e317-e327.	4.6	71
96	Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 212-218.	0.4	71
97	Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. <i>Cancer</i> , 2017, 123, 294-302.	4.1	70
98	Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2018, 4, 1413.	7.1	69
99	Impact of the variant allele frequency of <i>ASXL1</i> , <i>DNMT3A</i> , <i>JAK2</i> , <i>TET2</i> , <i>TP53</i> , and <i>NPM1</i> on the outcomes of patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 765-774.	4.1	69
100	Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. <i>American Journal of Hematology</i> , 2018, 93, 371-374.	4.1	68
101	Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. <i>American Journal of Hematology</i> , 2022, 97, 1236-1256.	4.1	68
102	Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia. <i>Cancer</i> , 2007, 110, 340-344.	4.1	66
103	Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. <i>Lancet Haematology</i> , 2018, 5, e411-e421.	4.6	66
104	Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. <i>Lancet Haematology</i> , 2015, 2, e118-e128.	4.6	65
105	Recent advances in the treatment of acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2606-2621.	1.3	65
106	Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. <i>Blood</i> , 2011, 117, 1822-1827.	1.4	64
107	Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2012, 87, 687-691.	4.1	63
108	Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 426-435.	4.1	63

#	ARTICLE	IF	CITATIONS
109	Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2019, 125, 2579-2586.	4.1	63
110	Immunotherapy in Acute Myeloid Leukemia: Where We Stand. <i>Frontiers in Oncology</i> , 2021, 11, 656218.	2.8	63
111	Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as frontline regimen in patients with core binding factor acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2014, 89, 964-968.	4.1	62
112	A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. <i>Blood</i> , 2018, 132, 1664-1674.	1.4	62
113	Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response. <i>Journal of Clinical Oncology</i> , 2009, 27, 3659-3663.	1.6	61
114	Early results of lower dose dasatinib (50%mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. <i>Cancer</i> , 2018, 124, 2740-2747.	4.1	61
115	Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. <i>Cancer</i> , 2019, 125, 4181-4192.	4.1	61
116	Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. <i>American Journal of Hematology</i> , 2021, 96, 282-291.	4.1	59
117	Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. <i>Lancet Oncology</i> , The, 2012, 13, 1096-1104.	10.7	58
118	Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2014, 89, 282-287.	4.1	58
119	Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. <i>Cancer</i> , 2018, 124, 325-334.	4.1	57
120	Treating Leukemia in the Time of COVID-19. <i>Acta Haematologica</i> , 2021, 144, 132-145.	1.4	57
121	Maintenance therapy in AML: The past, the present and the future. <i>American Journal of Hematology</i> , 2019, 94, 1254-1265.	4.1	56
122	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1876-1883.	5.2	56
123	Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. <i>Oncotarget</i> , 2018, 9, 9714-9727.	1.8	56
124	HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. <i>Cancer</i> , 2014, 120, 373-380.	4.1	54
125	A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2018, 93, 277-285.	4.1	54
126	Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. <i>Acta Haematologica</i> , 2020, 143, 567-573.	1.4	53



#	ARTICLE	IF	CITATIONS
127	Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , 2021, 7, 1213.	7.1	53
128	Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 763-763.	1.4	53
129	Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017. <i>American Journal of Hematology</i> , 2021, 96, 650-658.	4.1	52
130	Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 155-162.e1.	0.4	51
131	Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. <i>American Journal of Hematology</i> , 2020, 95, 612-622.	4.1	51
132	CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 749-755.	3.5	50
133	Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3 internal tandem duplication genotypes. <i>Cancer</i> , 2019, 125, 1091-1100.	4.1	50
134	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. <i>Blood Cancer Discovery</i> , 2021, 2, 125-134.	5.0	50
135	Chronic myeloid leukemia: First-line drug of choice. <i>American Journal of Hematology</i> , 2016, 91, 59-66.	4.1	49
136	Acute lymphoblastic leukemia in adolescents and young adults. <i>Cancer</i> , 2017, 123, 2398-2403.	4.1	49
137	Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. <i>Cancer</i> , 2017, 123, 459-467.	4.1	49
138	Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 559-567.	0.4	48
139	Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≥60 years with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2013, 88, 961-966.	4.1	46
140	Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). <i>American Journal of Hematology</i> , 2016, 91, 227-232.	4.1	46
141	TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. <i>Blood</i> , 2022, 140, 58-72.	1.4	46
142	Molecular monitoring in chronic myeloid leukemia. <i>Cancer</i> , 2008, 112, 2112-2118.	4.1	44
143	Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up. <i>Leukemia Research</i> , 2015, 39, 520-524.	0.8	44
144	Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2018, 124, 2151-2160.	4.1	44

#	ARTICLE	IF	CITATIONS
145	Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2013, 88, 831-837.	4.1	43
146	Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. <i>Cancer</i> , 2018, 124, 1722-1732.	4.1	43
147	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e523-e533.	4.6	43
148	Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. <i>American Journal of Hematology</i> , 2021, 96, 589-598.	4.1	42
149	Poor outcomes associated with +der(22)t(9;22) and $\hat{9}/9p$ in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. <i>American Journal of Hematology</i> , 2017, 92, 238-243.	4.1	41
150	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3848-3857.	1.6	41
151	Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2015, 121, 2375-2382.	4.1	40
152	Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2018, 93, 84-90.	4.1	40
153	Recent Advances in Managing Acute Lymphoblastic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 330-342.	3.8	40
154	Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. <i>American Journal of Hematology</i> , 2017, 92, 331-337.	4.1	39
155	Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 257-265.	0.4	39
156	Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. <i>American Journal of Hematology</i> , 2017, 92, 599-606.	4.1	38
157	Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults. <i>American Journal of Hematology</i> , 2018, 93, 286-295.	4.1	38
158	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 3755-3766.	4.1	38
159	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 4430-4439.	4.1	37
160	Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. <i>Blood Advances</i> , 2020, 4, 5336-5342.	5.2	37
161	A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2489-2492.	7.2	37
162	High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. <i>Blood Advances</i> , 2022, 6, 4006-4014.	5.2	37

#	ARTICLE	IF	CITATIONS
163	A phase I&II study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Cancer</i> , 2011, 117, 1236-1244.	4.1	36
164	Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2012, 157, 312-320.	2.5	36
165	Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7014-7014.	1.6	36
166	Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. <i>American Journal of Hematology</i> , 2015, 90, 193-196.	4.1	35
167	Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. <i>Blood Advances</i> , 2018, 2, 1807-1816.	5.2	34
168	Prognosis of patients with intermediate risk IPSS myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS. <i>American Journal of Hematology</i> , 2018, 93, 1245-1253.	4.1	34
169	Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. <i>Blood Cancer Journal</i> , 2020, 10, 81.	6.2	34
170	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Haematologica</i> , 2021, 106, 2121-2130.	3.5	34
171	A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 3761-3771.	4.1	34
172	Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 283-283.	1.4	34
173	Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 2193-2205.	4.1	33
174	Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. <i>Cancer</i> , 2021, 127, 2648-2656.	4.1	33
175	Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2022, 97, 856-864.	4.1	33
176	Hypomethylating agent and venetoclax with FLT3 inhibitor &triple therapy in older/unfit patients with FLT3 mutated AML. <i>Blood Cancer Journal</i> , 2022, 12, 77.	6.2	33
177	Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It. <i>Current Oncology Reports</i> , 2017, 19, 6.	4.0	32
178	Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. <i>American Journal of Hematology</i> , 2017, 92, E114-E117.	4.1	32
179	Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. <i>American Journal of Hematology</i> , 2017, 92, 279-285.	4.1	32
180	Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. <i>Leukemia Research</i> , 2020, 88, 106283.	0.8	32

#	ARTICLE	IF	CITATIONS
181	Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. <i>Blood Cancer Journal</i> , 2021, 11, 162.	6.2	32
182	Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. <i>Cancer</i> , 2017, 123, 629-637.	4.1	31
183	Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. <i>Blood</i> , 2021, 138, 1373-1377.	1.4	31
184	Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 1035-1043.	4.1	31
185	Impact of comorbidities by ACE27 in the revised iPSS for patients with myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2014, 89, 509-516.	4.1	30
186	Dorsal column myelopathy after intrathecal chemotherapy for leukemia. <i>American Journal of Hematology</i> , 2017, 92, 155-160.	4.1	30
187	Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 905-913.	4.1	30
188	A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 3867-3867.	1.4	30
189	Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens. <i>JAMA Oncology</i> , 2022, 8, 1340.	7.1	30
190	Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. <i>Haematologica</i> , 2013, 98, 1686-1688.	3.5	29
191	Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management. <i>Cancer</i> , 2020, 126, 1152-1160.	4.1	29
192	Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. <i>Annals of Hematology</i> , 2020, 99, 2215-2229.	1.8	29
193	Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. <i>Blood Advances</i> , 2020, 4, 6117-6126.	5.2	29
194	Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. <i>Leukemia</i> , 2021, 35, 3044-3058.	7.2	29
195	Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1288-1295.	4.1	28
196	The clinical development of antibody-drug conjugates lessons from leukaemia. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 418-433.	27.6	28
197	Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 193-200.	1.7	27
198	A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017, 92, 660-667.	4.1	26

#	ARTICLE	IF	CITATIONS
199	Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2019, 94, 1388-1395.	4.1	26
200	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. <i>Lancet Haematology</i> , 2022, 9, e350-e360.	4.6	26
201	Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2018, 8, 369.	2.8	25
202	Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. <i>International Journal of Hematology</i> , 2019, 109, 545-552.	1.6	25
203	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. <i>American Journal of Hematology</i> , 2020, 95, 144-150.	4.1	25
204	Evaluation and management of measurable residual disease in acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072091002.	2.5	25
205	Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. <i>American Journal of Hematology</i> , 2022, 97, 68-78.	4.1	25
206	Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. <i>Cancer Medicine</i> , 2019, 8, 6559-6565.	2.8	24
207	Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 187, 543-545.	2.5	24
208	Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 2025-2038.	4.1	24
209	Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. <i>Cancer</i> , 2021, 127, 4213-4220.	4.1	24
210	Outcomes of acute lymphoblastic leukemia with <i>KMT2A</i> ( <i>MLL</i> ) rearrangement: the MD Anderson experience. <i>Blood Advances</i> , 2021, 5, 5415-5419.	5.2	24
211	Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Blood</i> , 2019, 134, 285-285.	1.4	24
212	Myeloid neoplasms with concurrent <i>BCR-ABL1</i> and <i>CBFB</i> rearrangements: A series of 10 cases of a clinically aggressive neoplasm. <i>American Journal of Hematology</i> , 2017, 92, 520-528.	4.1	23
213	Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. <i>Cancer</i> , 2018, 124, 2534-2540.	4.1	23
214	Prediction for sustained deep molecular response of <i>BCR-ABL1</i> levels in patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2018, 124, 1160-1168.	4.1	23
215	Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 1000-1007.	4.1	23
216	Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes. <i>Current Opinion in Hematology</i> , 2018, 25, 146-153.	2.5	22

#	ARTICLE	IF	CITATIONS
217	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (IFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. <i>Leukemia</i> , 2021, 35, 3421-3429.	7.2	22
218	The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 365-373.	2.4	21
219	Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent $CD33$ expression and <i>in vitro</i> response to targeted $CD33$ therapy. <i>British Journal of Haematology</i> , 2019, 186, 538-548.	2.5	21
220	Recent Advances in Adult Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 106-118.	2.3	21
221	Long-term results of frontline dasatinib in chronic myeloid leukemia. <i>Cancer</i> , 2020, 126, 1502-1511.	4.1	21
222	The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 302-306.	0.4	20
223	SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 439-446.	0.4	20
224	Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. <i>American Journal of Hematology</i> , 2019, 94, 1382-1387.	4.1	20
225	Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 207-223.	2.5	20
226	Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. <i>Blood Cancer Journal</i> , 2020, 10, 61.	6.2	20
227	Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. <i>Cancer</i> , 2019, 125, 2233-2241.	4.1	19
228	The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. <i>American Journal of Hematology</i> , 2021, 96, 241-250.	4.1	19
229	Impact of frontline treatment approach on outcomes of myeloid blast phase CML. <i>Journal of Hematology and Oncology</i> , 2021, 14, 94.	17.0	19
230	Only $SF3B1$ mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. <i>Cancer</i> , 2021, 127, 3552-3565.	4.1	19
231	Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida). <i>Blood</i> , 2019, 134, 290-290.	1.4	19
232	Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2015, 126, 83-83.	1.4	19
233	Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 163-168.e2.	0.4	18
234	$TP53$ mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. <i>Cancer</i> , 2017, 123, 3717-3724.	4.1	18

#	ARTICLE	IF	CITATIONS
235	Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071984949.	2.5	18
236	Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7001-7001.	1.6	18
237	Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7013-7013.	1.6	18
238	Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7051-7051.	1.6	18
239	Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-“negative acute lymphoblastic leukemia. <i>Cancer</i> , 2016, 122, 3812-3820.	4.1	17
240	Factors associated with risk of central nervous system relapse in patients with non-“core binding factor acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017, 92, 924-928.	4.1	17
241	P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with <i>&lt;i&gt;FLT3&lt;/i&gt;</i> internal tandem duplication and worse relapse-“free survival. <i>American Journal of Hematology</i> , 2018, 93, 1376-1383.	4.1	17
242	NPM1mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information inNPM1-“mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, E158-E160.	4.1	17
243	An effective chemotherapy-“free regimen of ponatinib plus venetoclax for relapsed/refractory <i>&lt;scp&gt;P&lt;/scp&gt;</i> hiladelphia chromosome-“positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E229-E232.	4.1	17
244	The cure of leukemia through the optimist's prism. <i>Cancer</i> , 2022, 128, 240-259.	4.1	17
245	Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. <i>American Journal of Hematology</i> , 2022, 97, E62.	4.1	17
246	Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. <i>Blood Advances</i> , 2022, 6, 3027-3035.	5.2	17
247	Outcome of adults with relapsed/refractory T-“cell acute lymphoblastic leukemia or lymphoblastic lymphoma. <i>American Journal of Hematology</i> , 2020, 95, E245-E247.	4.1	16
248	Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. <i>Clinical Cancer Research</i> , 2021, 27, 2742-2754.	7.0	16
249	Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2021, 35, 1494-1499.	7.2	16
250	Treatment of acute lymphoblastic leukemia in older adults: now and the future. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 266-274.	0.3	16
251	Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 91-99.	2.3	15
252	Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-“positive acute lymphoblastic leukemia treated with hyper-“CVAD and dasatinib. <i>Cancer</i> , 2021, 127, 2641-2647.	4.1	15

#	ARTICLE	IF	CITATIONS
253	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. <i>Blood</i> , 2019, 134, 2637-2637.	1.4	15
254	Improved outcomes among newly diagnosed patients with <i>FMS</i> -like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. <i>American Journal of Hematology</i> , 2022, 97, 329-337.	4.1	15
255	Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. <i>Cancer</i> , 2019, 125, 3219-3224.	4.1	14
256	Long-term results of a phase 2 trial of nilotinib 400mg twice daily in newly diagnosed patients with chronic phase chronic myeloid leukemia. <i>Cancer</i> , 2020, 126, 1448-1459.	4.1	14
257	Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. <i>Blood</i> , 2020, 136, 15-17.	1.4	14
258	Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective case-control study. <i>American Journal of Hematology</i> , 2013, 88, 198-200.	4.1	13
259	Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. <i>American Journal of Hematology</i> , 2017, 92, 351-358.	4.1	13
260	Clinical outcomes in adult patients with aplastic anemia: A single institution experience. <i>American Journal of Hematology</i> , 2017, 92, 1295-1302.	4.1	13
261	Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 914-924.	4.1	13
262	Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study. <i>Blood</i> , 2020, 136, 9-11.	1.4	13
263	Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2015, 126, 3721-3721.	1.4	13
264	Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. <i>Journal of Hematology and Oncology</i> , 2022, 15, 12.	17.0	13
265	L-carnitine and Vitamin B Complex for the Treatment of Pegasparginase-induced Hyperbilirubinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e191-e195.	0.4	12
266	Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study. <i>American Journal of Hematology</i> , 2021, 96, E379-E383.	4.1	12
267	Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. <i>Blood</i> , 2018, 132, 36-36.	1.4	12
268	Prediction of survival with intensive chemotherapy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 865-876.	4.1	12
269	A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 2161-2170.	1.3	12
270	A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 395-400.e1.	0.4	11



#	ARTICLE	IF	CITATIONS
271	Relapsed B-acute lymphoblastic leukemia with aberrant myeloperoxidase expression following CAR T-cell therapy: A diagnostic challenge. <i>American Journal of Hematology</i> , 2019, 94, 1049-1051.	4.1	11
272	Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. <i>American Journal of Hematology</i> , 2019, 94, 408-416.	4.1	11
273	Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 2647-2647.	1.4	11
274	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. <i>Blood</i> , 2020, 136, 42-43.	1.4	11
275	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. <i>Blood</i> , 2016, 128, 588-588.	1.4	11
276	Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2017, 130, 815-815.	1.4	11
277	Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2023, 98, .	4.1	11
278	A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. <i>American Journal of Hematology</i> , 2019, 94, 74-79.	4.1	10
279	Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. <i>Leukemia and Lymphoma</i> , 2020, 61, 2012-2015.	1.3	10
280	Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e871-e882.	0.4	10
281	Ciliteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072093061.	2.5	10
282	Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2020, 95, 734-739.	4.1	10
283	Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. <i>Cancer</i> , 2021, 127, 381-390.	4.1	10
284	Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2021, 127, 3381-3389.	4.1	10
285	Development of TP53 mutations over the course of therapy for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 1420-1428.	4.1	10
286	Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). <i>American Journal of Hematology</i> , 2021, 96, E246-E249.	4.1	9
287	Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. <i>Leukemia</i> , 2022, 36, 1253-1260.	7.2	9
288	Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2022, Volume 12, 7-16.	2.7	9

#	ARTICLE	IF	CITATIONS
289	Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens. American Journal of Hematology, 2017, 92, E595-E597.	4.1	8
290	The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. American Journal of Hematology, 2020, 95, 1127-1134.	4.1	8
291	Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. American Journal of Hematology, 2021, 96, E50-E53.	4.1	8
292	Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia.. Journal of Clinical Oncology, 2019, 37, 7034-7034.	1.6	8
293	Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 338-344.	0.4	7
294	Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML). Blood, 2015, 126, 2541-2541.	1.4	7
295	Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML) T J ETQq1.1 0.784314 rgBT	1.6	7
296	Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. American Journal of Hematology, 2022, 97, .	4.1	7
297	Similar Outcome of Patients With Chronic Myeloid Leukemia Treated With Imatinib in or Out of Clinical Trials. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 693-699.	0.4	6
298	Antibody based therapy in relapsed acute lymphoblastic leukemia. Best Practice and Research in Clinical Haematology, 2020, 33, 101225.	1.7	6
299	A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory precursor cell acute lymphoblastic leukemia. Cancer, 2021, 127, 4190-4197.	4.1	6
300	Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2020, 38, 7539-7539.	1.6	6
301	Treatment-free remission in chronic myeloid leukemia. Clinical Advances in Hematology and Oncology, 2019, 17, 686-696.	0.3	6
302	Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of $10^{-4}$ and higher. American Journal of Hematology, 2022, 97, 1135-1141.	4.1	6
303	Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome. American Journal of Hematology, 2017, 92, E168-E171.	4.1	5
304	Phase 1/2 study of DFP10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer, 2019, 125, 1665-1673.	4.1	5
305	GATA3 rs3824662A allele in B-cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with CRLF2 rearrangement and poor prognosis. American Journal of Hematology, 2021, 96, E71-E74.	4.1	5
306	Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer, 2021, 127, 1894-1900.	4.1	5

#	ARTICLE	IF	CITATIONS
307	Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. <i>Blood Cancer Journal</i> , 2021, 11, 52.	6.2	5
308	Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. <i>Cancer</i> , 2021, 127, 3113-3124.	4.1	5
309	Long term outcome of Hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. <i>Blood Advances</i> , 2021, 5, 3913-3918.	5.2	5
310	SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 61-66.	0.4	5
311	Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes. <i>Blood</i> , 2020, 136, 26-28.	1.4	5
312	Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 7013-7013.	1.6	5
313	Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2775-2777.	1.3	4
314	Current Approaches to Philadelphia Chromosome-Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant. <i>Current Oncology Reports</i> , 2021, 23, 95.	4.0	4
315	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis. <i>Blood</i> , 2018, 132, 34-34.	1.4	4
316	Interim Results of the Phase I/II Study of the Ponatinib, Venetoclax and Dexamethasone for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020, 136, 11-12.	1.4	4
317	Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. <i>American Journal of Hematology</i> , 2022, 97, 885-894.	4.1	4
318	Real-life incidence of thrombotic events in leukemia patients treated with ponatinib. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	4
319	The face of remission induction. <i>British Journal of Haematology</i> , 2020, 188, 101-115.	2.5	3
320	Monoclonal antibodies in frontline acute lymphoblastic leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101226.	1.7	3
321	Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. <i>British Journal of Haematology</i> , 2020, 191, e77-e81.	2.5	3
322	The Hyper-CVAD Regimen is an Optimal Pediatric-inspired Regimen for Adolescents and Adults With Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 63-65.	0.4	3
323	A new era in the treatment of acute lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 1563-1564.	1.4	3
324	<sc>FLT3</sc> inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed <sc>Acute Myeloid Leukemia</sc> with very low <sc>FLT3</sc> allelic burden. <i>American Journal of Hematology</i> , 2021, 96, E275-E279.	4.1	3

#	ARTICLE	IF	CITATIONS
325	Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories. <i>Blood</i> , 2019, 134, 1344-1344.	1.4	3
326	Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 751-758.	1.8	3
327	SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 471-479.	0.4	2
328	Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). <i>American Journal of Hematology</i> , 2020, 95, E326-E329.	4.1	2
329	Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement. <i>Blood</i> , 2019, 134, 2582-2582.	1.4	2
330	Reply to ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 4935-4936.	4.1	1
331	Management of Older Patients with Acute Lymphocytic Leukemia – Novel Treatment Strategies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S30-S31.	0.4	1
332	Outcome of Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma with Early T-Cell Precursor-like Immunophenotype with Strong CD5 Expression. <i>Blood</i> , 2020, 136, 38-40.	1.4	1
333	Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e836-e843.	0.4	1
334	Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 347-356.	2.5	0
335	Reply to Mini-CHCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?. <i>Cancer</i> , 2019, 125, 3891-3892.	4.1	0
336	CML Therapy: A Focus on Second- and Third-Generation Tyrosine Kinase Inhibitors. <i>Hematologic Malignancies</i> , 2021, , 61-76.	0.2	0
337	Hyper-CVAD in 2021: Lessons Learned and New Approaches. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S82-S84.	0.4	0
338	Treatment of Graft Failure with Fludarabine (Flu), Antithymocyte Globulin (ATG) and a Second Allogeneic Stem Cell Transplantation (SCT).. <i>Blood</i> , 2005, 106, 2734-2734.	1.4	0
339	Frontline Therapy of Newly Diagnosed Acute Lymphoblastic Leukemia. <i>Hematologic Malignancies</i> , 2021, , 169-184.	0.2	0
340	Minimal or Measurable Residual Disease in Acute Lymphoblastic Leukemia. <i>Hematologic Malignancies</i> , 2021, , 205-218.	0.2	0
341	Prediction for sustained deep molecular response for treatment-free remission. <i>Leukemia and Lymphoma</i> , 2022, 63, 5-6.	1.3	0